We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Botox -- an option for treatment of male lower urinary tract symptoms?
- Authors
Ilie, P. C.; Chancellor, M. B.; Chuang, Y. C.; Mischianu, D.
- Abstract
Benign prostatic hyperplasia (BPH) is a highly prevalent nonmalignant condition which occurs commonly in men over the age of 60. Botulinum toxin type A (BoNT-A) used selectively can be a therapeutic solution for those patients. This paper aims to update the knowledge referring to the effects of BoNT-A on the prostate. Intramuscular injection of BoNT-A induces inhibition of acethylcholine release at the neuromuscular junction and causes temporary chemodenervation with paralyzing effects and atrophy of striated muscle as well as the smooth muscle fiber. BoNT-A also causes inhibitory effects on the autonomic nervous system affecting the glandular tissue, action responsible for diffuse atrophy and apoptosis of nasal and prostate glands. BoNT-A injected at the prostatic level induced: increase of the urinary flow, decrease of the prostatic volume, of the residual volume, of the IPSS symptom score, as well as of PSA. The effects maintained for 6-12 months and no side effects were reported in any patient. BPH is an important issue of public health and any new treatment option is good news for the patient population as well as for the urological community. Although the clinical series demonstrates efficacy at 30 months more studies are necessary in order to identify the mechanisms by which BoNT-A affects the prostate, the ideal dose and the duration of effect.
- Subjects
BOTULINUM toxin; URINARY tract infection treatment; BENIGN prostatic hyperplasia; HYPERPLASIA treatment; DISEASES in men; MUSCULAR atrophy; PROSTATE; AUTONOMIC nervous system; APOPTOSIS; INTRAMUSCULAR injections
- Publication
Romanian Journal of Urology, 2009, Vol 8, Issue 3, p9
- ISSN
1223-0650
- Publication type
Article